Floatz logo

Emapalumab

Refractory Non-Hodgkin Lymphoma

Marcela V. Maus, M.D.,Ph.D.monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Refractory Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Axicabtagene Ciloleucel
Lyell Immunopharma, Inc.
Phase 3BB
Olaparib
OHSU Knight Cancer Institute
Phase 2BB
Vesanoid
Rita Assi
Phase 2B
VEMURAFENIB
OHSU Knight Cancer Institute
Phase 2B
cd19/22 cart
The First Affiliated Hospital of Soochow University
Phase 2B

View all 16 →

Same molecule, other indications

Emapalumab is also rated in:

non-Hodgkin lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
diffuse large B-cell lymphomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →